News
AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Anaptys Announces Stock Repurchase Plan. SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative ...
AnaptysBio Inc’s (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities ...
Yatin Suneja from Guggenheim set a price target of 54.0 for ANAB. Skip to main content. Nasdaq+. Weekly Macro+. Scorecard. Market Activity. U.S. Market Activity-> Stocks; Options ...
AnaptysBio (ANAB) stock gains as H.C. Wainwright upgrades the stock on promising Phase 2b trial data for its rheumatoid arthritis therapy rosnilimab. Read more here.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AnaptysBio Inc (Symbol: ANAB), where a total of 12,964 contracts have traded so far ...
AnaptysBio (ANAB) stock dips as rival J&J's (JNJ) trial data for its anti-inflammatory agent similar to ANAB's lead asset disappoints in ulcerative colitis. Read more here.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results